Mia's Feed
Medical News & Research

AI Innovation Enables Detection of Fatty Liver Disease via Chest X-Rays

AI Innovation Enables Detection of Fatty Liver Disease via Chest X-Rays

Share this article

Innovative AI model analyzes routine chest X-rays to detect fatty liver disease, offering a cost-effective and accessible diagnostic method that could transform early screening strategies.

2 min read

Recent advancements in artificial intelligence (AI) have paved the way for new, more accessible methods to diagnose fatty liver disease, a condition affecting approximately one in four individuals globally. Traditionally, identifying fatty liver requires specialized imaging tests such as ultrasounds, CT scans, or MRIs, which can be costly and less readily available. However, researchers from Osaka Metropolitan University have developed an innovative AI model that leverages routine chest X-ray images to detect this condition.

While chest X-rays are primarily used to evaluate the lungs and heart, they also inadvertently capture parts of the liver. This serendipitous overlap allows for deep learning models to analyze these images for signs of fatty liver disease. A study involving 6,599 X-ray images from 4,414 patients utilized controlled attenuation parameter (CAP) scores to train the AI. The model demonstrated high accuracy, with an area under the receiver operating characteristic curve (AUC) between 0.82 and 0.83, indicating strong diagnostic potential.

The integration of AI with commonly performed and affordable chest X-rays could significantly improve early detection of fatty liver disease. Professor Sawako Uchida-Kobayashi highlighted the potential impact, stating that developing such diagnostic methods using readily available imaging could enhance screening efforts and facilitate timely treatment.

This breakthrough was detailed in the journal Radiology: Cardiothoracic Imaging and represents a promising step toward more efficient and cost-effective liver disease diagnostics. As research progresses, this approach could become a routine part of medical assessments, enabling broader screening and better patient outcomes.

Source: https://medicalxpress.com/news/2025-06-ai-fatty-liver-disease-chest.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

How Wegovy and Mounjaro May Impact Contraceptive Effectiveness

Recent studies indicate that weight loss drugs Wegovy and Mounjaro may reduce the effectiveness of oral contraceptives by altering drug absorption, necessitating additional contraceptive measures.

New Hope for Treating Obesity-Related Breathing Disorders with Setmelanotide

This innovative research highlights the potential of setmelanotide, an FDA-approved drug, in treating obesity-linked sleep breathing disorders by targeting brain pathways that regulate respiration.

Promising Results for HER3-Targeted Antibody-Drug Conjugate in Treatment-Resistant Solid Tumors

Early clinical trial results show that the HER3-targeted antibody-drug conjugate DB-1310 offers hope for patients with resistant advanced solid tumors, including EGFR-mutant non-small cell lung cancer, by extending survival and maintaining manageable side effects.